Bionor’s CSO Maja Sommerfelt was honorable speaker at Vaccines 2017

CSO Maja Sommerfelt was invited as an honorable speaker at Vaccines 2017 in Baltimore, USA, where she presented data from the REDUC clinical trial and chaired the session “HIV/AIDS Vaccines & Clinical Trials, Human Vaccines – Infectious & Non Infectious Diseases & Immunology/Animal models”

Doctoral thesis at Oslo University Hospital based on clinical studies carried out in collaboration with Bionor Pharma

Oslo, 07.12.2016. Cand. Med. Kristin Brekke will defend her doctoral thesis entitled “Therapeutic vaccination in chronic HIV infection – clinical studies” on Thursday 8th December at Oslo University Hospital. Link to more information (in Norwegian). Her thesis describes analyses from three clinical trials that have been carried out at Oslo University Hospital (Ullevål) in …

Read more

Poster presentation at NIH “Strategies for an HIV Cure” meeting in Bethesda, Maryland US

Bionor Pharma ASA has been selected to present a poster entitled “Approaching HIV Functional Cure Applying Vacc-4x, a peptide-based HIV Therapeutic Vaccine: Clinical Development Methodological Considerations” at the National Institute of Health (NIH) “Strategies for an HIV Cure” meeting from 14th-16th November 2016, in Bethesda, Maryland, USA. Bionor At NIH 2016 The poster compiles data …

Read more

Poster presentation at the 18th Institute of Human Virology Annual Conference

Preliminary data from a Bionor research project supported by the Research Council of Norway GLOBVAC program will be presented as a poster today at the 18th Annual International Meeting of the Institute of Human Virology which takes places from 19-22 September in Baltimore, Maryland USA ( The poster will be presented by Dr. Pete Smith, …

Read more

Bionor provides an update on scientific collaborations

(Oslo, Norway, 13 June 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR), today provides an update on scientific collaborations in relation to the company’s HIV immunotherapy pipeline. On 31 May 2016, the Board of Directors announced a clinical strategy with continued focus on HIV immunotherapy and functional cure, which are complex scientific areas, and best pursued through …

Read more

The peer-reviewed and highly recognized journal ‘The Lancet HIV’ has accepted the results of the REDUC Part B trial for publication

(Oslo, Norway, 9 June 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR), announced today that the positive results from the clinical trial REDUC Part B (BPC01-001) will be published for the first time in the peer-reviewed and highly recognized journalThe Lancet HIV. The manuscript, entitled “The combined effect of Vacc-4x/rhuGM-CSF vaccination and romidepsin on the HIV-1 reservoir: …

Read more

The final assay in Bionor’s REDUC trial for measuring latent HIV reservoir, Integrated HIV DNA, supports the Shock & Kill approach using Vacc-4x and romidepsin

REDUC Part B results were presented today at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) (Oslo, Norway, 23 February 2016) Bionor Pharma ASA (OSE:BIONOR), a biopharmaceutical company focused on advancing a functional cure for HIV, announces that the third and final assay for measuring latent HIV reservoir size, the primary endpoint in the …

Read more

Bionor files first clinical trial application for BIOSKILL

(Oslo, Norway, 17 November 2015) Bionor Pharma ASA (OSE:BIONOR) today announced the submission of a clinical trial application (CTA) to the Danish Medicines Agency requesting approval to initiate BIOSKILL in Denmark. BIOSKILL (BIOnor Shock and KILL) will enroll patients internationally and further CTAs will be submitted to national medicines agencies in the coming months. BIOSKILL …

Read more

Results of the REDUC study Part A published in the journal PLoS Pathogens

(Oslo, Norway, 18 September 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, today announces the publication of the manuscript “The Depsipeptide Romidepsin Reverses HIV-1 Latency in vivo” in the peer-reviewed journal PLoS Pathogens. Ole Schmeltz Søgaard from Aarhus University Hospital in …

Read more

Bionor announces promising results from an interim analysis of the functional cure HIV study REDUC Part B

Indicating killing of reactivated HIV virus and reduction in latent viral reservoir when patients receive the therapeutic vaccine Vacc-4x prior to romidepsin The study confirms that Bionor’s proprietary peptide vaccine, Vacc-4x, is a safe and tolerated potential functional cure for HIV (Oslo, Norway, 4 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing …

Read more